Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
Department of Cardiovascular Medicine, Kurashiki Central Hospital, Ohara HealthCare Foundation, Okayama, 710-8602, Japan.
J Physiol Sci. 2023 Apr 12;73(1):7. doi: 10.1186/s12576-023-00861-9.
Although suppression of sympathetic activity is suggested as one of the underlying mechanisms for the cardioprotective effects afforded by sodium-glucose cotransporter 2 (SGLT2) inhibitors, whether the modulation of glucose handling acutely affects sympathetic regulation of arterial pressure remains to be elucidated. In Goto-Kakizaki diabetic rats, we estimated the open-loop static characteristics of the carotid sinus baroreflex together with urine glucose excretion using repeated 11-min step input sequences. After the completion of the 2nd sequence, an SGLT2 inhibitor empagliflozin (10 mg kg) or vehicle solution was administered intravenously (n = 7 rats each). Empagliflozin did not significantly affect the baroreflex neural or peripheral arc, despite significantly increasing urine glucose excretion (from 0.365 ± 0.216 to 8.514 ± 0.864 mg·min·kg, P < 0.001) in the 7th and 8th sequences. The possible sympathoinhibitory effect of empagliflozin may be an indirect effect associated with chronic improvements in renal energy status and general disease conditions.
尽管抑制交感神经活动被认为是钠-葡萄糖共转运蛋白 2 (SGLT2) 抑制剂提供的心脏保护作用的潜在机制之一，但葡萄糖处理的调节是否会急性影响动脉压力的交感调节仍有待阐明。在 Goto-Kakizaki 糖尿病大鼠中，我们使用重复的 11 分钟阶跃输入序列来估计颈动脉窦压力反射的开环静态特性以及尿葡萄糖排泄。在第 2 个序列完成后，静脉给予 SGLT2 抑制剂恩格列净（10 mg·kg）或载体溶液（每组 7 只大鼠）。尽管恩格列净显著增加了尿葡萄糖排泄（从第 7 个和第 8 个序列的 0.365 ± 0.216 到 8.514 ± 0.864 mg·min·kg，P < 0.001），但对压力反射神经或外周弧没有显著影响。恩格列净的可能的交感抑制作用可能是与慢性改善肾脏能量状态和一般疾病状况相关的间接作用。
